Methods: In TWENTE - a prospective, randomized DES trial - PCI patients were randomized for treatment with contemporary Resolute or Xience V stents. Clinical endpoints were adjudicated by an external independent clinical events committee (Cardialysis CRO, Rotterdam, The Netherlands). Target vessel failure (TVF; cardiac death, target vessel-related myocardial infarction, and clinically-indicated target vessel revascularization), the primary endpoint of the TWENTE trial, was assessed after 2 years.
Results: Among the 1,391 patients of the TWENTE trial, 362 (26%) patients were treated for at least one bifurcation lesion. Of these patients, 179 and 183 were randomized for treatment with Resolute and Xience V stents, respectively. At 2-year follow-up, TVF (12.8% vs. 11.5%; p=0.69) and a patient-oriented composite endpoint (17.3% vs. 16.9%; p=0.92) did not differ significantly between stent arms. In addition, rates of definite and or probable stent thrombosis were low and similar for both stent arms (0.6% vs. 0.5%; p=0.99). Within 213 (15.3%) patients, who were treated for bifurcation lesions with an additional treatment of the side-branch, there was also no significant difference in TVF between patients treated with Resolute (n=98) and Xience V (n=115) (8.2% vs. 11.3%; p=0.44).
Conclusions: Treatment of bifurcation lesions with Resolute and Xience V stents resulted in favorable and similar outcomes after 2 years in the randomized TWENTE trial.
|Journal||Journal of the American College of Cardiology|
|Issue number||18, Suppl. 1|
|Publication status||Published - 2013|
|Event||25th Annual Scientific Symposium of Transcatheter Cardiovascular Therapeutics, TCT 2013 - San Francisco, United States|
Duration: 27 Oct 2013 → 1 Nov 2013
Conference number: 25